by Emily Burke, PhD | Nov 1, 2018 | Drug Development, Uncategorized
Squash That Bug The flu. Need we say more? Why yes. Yes, we do! Last week, we examined all things flu: we talked about the influenza virus structure, how the pesky pathogen makes us feel so lousy, and why the vaccine’s effectiveness isn’t always up to sniff. Er,... 
by Emily Burke, PhD | Apr 12, 2018 | Commercialization, Uncategorized
The Science Behind the Deal Earlier this week, news of the $8.7 billion acquisition of gene therapy company AveXis (Bannockburn, IL) by Novartis (Basel, Switzerland) made big biotech headlines. AveXis’ lead candidate, AVXS-101, is now in Phase III clinical... 
by Emily Burke, PhD | Mar 8, 2018 | Genetic Engineering, Uncategorized
MISSION IMPOSSIBLE: MEATLESS MEAT? Imagine biting into a juicy cheeseburger: the flavor, the texture, the smell. Now, imagine the cheeseburger meatless. Impossible? No. Impossible Foods, a Redwood City, CA-based company has used biotechnology to create a... 
by Emily Burke, PhD | Mar 9, 2017 | Immunology, Uncategorized
Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this... 
by Emily Burke, PhD | Feb 16, 2017 | Genetic Engineering, Uncategorized
Coming Soon To A Supermarket Near You Coming soon to a supermarket near you: apples that have been genetically modified to resist browning. Dubbed Arctic Apples, the plants were approved two years ago by the USDA and will begin appearing on... 
by Emily Burke, PhD | Nov 17, 2016 | Neuroscience, Uncategorized
A Big Pain The opioid addiction crisis gained attention at the highest levels of U.S. policy circles this past year. Presidential candidates that disagreed on nearly everything else vowed to make fighting the epidemic a priority if elected. In July, the U.S. Senate... 
